002422 Sichuan Kelun Pharmaceutical
- 33.67
- -0.04-0.12%
Sichuan Kelun Pharmaceutical News
With EPS Growth And More, Sichuan Kelun Pharmaceutical (SZSE:002422) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall S
Galaxy Securities: The pharmaceutical industry's revenue growth rate is slowing down in 2023, and the worst is expected to pass
The Zhitong Finance App learned that Galaxy Securities released a research report saying that judging from the pace of growth in the pharmaceutical industry, expectations for the whole year are low and moving high. 24Q1 is expected to be the lowest point for the whole year, and a recovery in the pharmaceutical industry's growth rate can be expected from 24Q2. Currently, more emphasis is placed on innovation and device export direction: 1) Pharmaceutical innovation industry upgrading; 2) Colon Pharmaceutical (002422.SZ), etc., a platform-based pharmaceutical company with excellent management; 3) domestic replacement of equipment and overseas exports of Mindray Healthcare (300760.SZ), etc.; 4) Third-party medical testing Jinyu Medicine (603882.SH), etc.; 5) upstream life science,
Zhitong A Share Sale Restriction and Release List | May 9
According to the Zhitong Finance App, the ban on restricted shares of 9 listed companies was lifted on May 9, with a total market value of about 1,244 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Zhongfu Industrial 600,595 share incentives, 1,585 million, Colon Pharmaceutical 002422, share incentives, 2.24910,000, Dream Lily 603,313 additional A shares, original shareholders placed and listed 85,2878 million, Design Institute 603,357 share incentives, limited circulation, 517.47 Wan Shennong Group 605296 share incentive limited circulation 466.5 million
Colon Pharmaceutical (002422.SZ) plans to subscribe for domestic shares issued by its holding subsidiary Colun Botai with a subscription amount of 603 million yuan
Glonghui, May 8 | Colun Pharmaceutical (002422.SZ) announced that in order to further advance the company's development strategy, ensure the orderly development of its holding subsidiary, Sichuan Colunbotai Biomedical Co., Ltd. (“Colunbotai”), maintain the stability of Colunbotai's shareholding structure, and enhance the competitiveness of Colunbotai, plans to issue targeted domestic shares to the company while issuing H shares on the Hong Kong Stock Exchange. The company plans to subscribe for all of its targeted domestic shares. The two sides signed the “Targeted Issuance of Shares Subscription Agreement” on May 8, 2024. The subscription price is based on exchange rate factors, and Colunbott is affiliated with the Hong Kong Federation
Are Robust Financials Driving The Recent Rally In Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Stock?
Sichuan Kelun Pharmaceutical's (SZSE:002422) stock is up by a considerable 34% over the past three months. Since the market usually pay for a company's long-term fundamentals, we decided to study th
Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 31x, you may consider Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) as an attractive investment with i
Colon Pharmaceutical (002422.SZ) Performance Report: 2023 net profit of 2,457 billion yuan increased 44.05% year-on-year
Gelonghui, April 10 | Colon Pharmaceutical (002422.SZ) announced its 2023 annual results report. In 2023, it achieved total operating income of 21,454 billion yuan, an increase of 12.69%; achieved net profit attributable to shareholders of listed companies of 2,457 billion yuan, an increase of 44.05%; realized net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 2,367 million yuan, an increase of 43.87% year on year; basic earnings per share were 1.69 yuan.
Colon Pharmaceuticals (002422.SZ): The core product, lucansastuzumab (sAC-TMT), published research results at the 2024 American Association for Cancer Research Annual Meeting
Colon Pharmaceutical (002422.SZ) announced that the company's holding subsidiary, Sichuan Colun Botai Biomedical Co., Ltd...
Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Shares Could Be 41% Below Their Intrinsic Value Estimate
Key Insights Sichuan Kelun Pharmaceutical's estimated fair value is CN¥51.22 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥30.22 suggests Sichuan Kelun Pharmaceutical is potent
Parenteral Nutrition Market Global Analysis and Forecasts to 2030, Featuring Fresenius Kabi, Grifols, Pfizer, Otsuka Pharmaceutical, Baxter, Sichuan Kelun Pharmaceutical, Vifor Pharma and Aculife
Colon Pharmaceutical (002422.SZ): The subsidiary's core product SKB264 (MK-2870) was recognized as a breakthrough therapy by the State Drug Administration for first-line treatment of locally advanced, recurrent, or metastatic PD-L1 negative TNBC that cann
Gelonghui, March 13 | Colon Pharmaceutical (002422.SZ) announced that the company recently learned that the core product SKB264 (also known as MK-2870) of the company's holding subsidiary, Sichuan Colunbotai Biomedical Co., Ltd. (hereinafter referred to as “Columbite”), was recently recognized as a breakthrough therapy by the National Drug Administration (hereinafter referred to as “NMPA”) Drug Evaluation Center (TNBC) for first-line treatment of locally advanced, recurrent, or metastatic PD-L1 negative triple-negative breast cancer (TNBC). This is SKB264 follow-up treatment
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug
The US Food and Drug Administration granted a Fast Track designation for a lung cancer drug developed by Sichuan Kelun Botai Biopharmaceutical, a unit of Sichuan Kelun Pharmaceutical (SHE:002422), acc
Colon Pharmaceuticals (002422.SZ): The subsidiary's main product, A400 (EP0031), was granted Fast Track Qualification by the US Food and Drug Administration
Glonghui, March 11 | Colon Pharmaceutical (002422.SZ) announced that the company recently learned that the main product A400 (RET) small molecule kinase inhibitor project during transfection (RET), also known as KL590586 or EP0031), has obtained fast-track qualification from the US Food and Drug Administration (FDA) for treating RET-positive non-small cell lung cancer (NSCLC).
The Three-year Returns for Sichuan Kelun Pharmaceutical's (SZSE:002422) Shareholders Have Been Favorable, yet Its Earnings Growth Was Even Better
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. Just
Colon Pharmaceutical (002422.SZ): A new product related to parenteral nutrition obtained drug registration approval
Colon Pharmaceutical (002422.SZ) issued an announcement that in the company's chemical “omega-3 triglycerides (2%)/...
Colon Pharmaceutical (002422.SZ): Omega-3 triglyceride (2%) medium/long chain fat milk/amino acid (16) /glucose (16%) injection obtained drug registration approval
Gelonghui March 1 | Colon Pharmaceutical (002422.SZ) announced that the company's chemical “omega-3 triglyceride (2%) medium/long chain fat milk/amino acid (16) /glucose (16%) injection” was recently approved for drug registration by the State Drug Administration. The omega-3 triglyceride (2%) medium/long chain fat milk/amino acid (16) /glucose (16%) injection is the 8th parenteral nutritional three-chamber bag approved by the company. It is also the first domestic three-chamber bag containing fish oil approved for both central and peripheral intravenous administration. The omega-3 fatty acids contained in the formula can regulate inflammation in the body
Colon Pharmaceutical (002422.SZ): Weight loss products have not yet been deployed
Gelonghui, Feb. 23丨An investor asked Colon Pharmaceuticals (002422.SZ) on the investor interactive platform, “Does your company currently plan to develop diet pills? Or does it already have a layout in the field of diet pills?” The company replied that the company has yet to lay out weight loss products, and the company will actively pay attention to cutting-edge trends in the industry and conduct comprehensive research and judgment.
Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Market Cap Dropped CN¥2.2b Last Week; Individual Investors Bore the Brunt
Key Insights Significant control over Sichuan Kelun Pharmaceutical by individual investors implies that the general public has more power to influence management and governance-related decisions A t
Colun Botai Bio-B (06990.HK): Controlling shareholder Colon Pharmaceuticals increased its H share holdings by 785,000
Glonghui, January 23 | Colun Botai Bio-B (06990.HK) issued an announcement and received a notice from the controlling shareholder Sichuan Colon Pharmaceutical Co., Ltd. (“Colon Pharmaceutical”). On January 22, 2024, Colon Pharmaceutical increased its holdings of the company's H shares by 785,000 through OTC bulk transactions through its wholly-owned subsidiary. The average price of each H share was HK$90.0. Immediately after completing the above increase in holdings, Colon Pharmaceuticals held an interest in the company's 150,123,385 shares, accounting for about 68.49% of the company's total share capital.
Analysis
Price Target
No Data
